Business Description
ISIN : US40131M1099
Total Employee Number:
2,506Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.62 | |||||
Equity-to-Asset | -0.12 | |||||
Debt-to-Equity | -7.61 | |||||
Debt-to-EBITDA | -3.95 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.56 | |||||
Beneish M-Score | -2.84 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 21.2 | |||||
3-Year EBITDA Growth Rate | 20.9 | |||||
3-Year EPS without NRI Growth Rate | 24.7 | |||||
3-Year FCF Growth Rate | 21.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 36.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 74.12 | |||||
9-Day RSI | 65.89 | |||||
14-Day RSI | 62.55 | |||||
3-1 Month Momentum % | 29.05 | |||||
6-1 Month Momentum % | 47.71 | |||||
12-1 Month Momentum % | 148.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.03 | |||||
Quick Ratio | 3.71 | |||||
Cash Ratio | 3.11 | |||||
Days Inventory | 79.31 | |||||
Days Sales Outstanding | 40.18 | |||||
Days Payable | 50.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.4 | |||||
Shareholder Yield % | -1.22 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 65.01 | |||||
Operating Margin % | -39.75 | |||||
Net Margin % | -38.33 | |||||
EBITDA Margin % | -36.36 | |||||
FCF Margin % | -20.35 | |||||
OCF Margin % | -15.65 | |||||
ROA % | -26.83 | |||||
ROIC % | -69.18 | |||||
3-Year ROIIC % | 46.7 | |||||
ROC (Joel Greenblatt) % | -143.4 | |||||
ROCE % | -31.93 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 18.7 | |||||
EV-to-EBIT | -52.38 | |||||
EV-to-Forward-EBIT | -52.3 | |||||
EV-to-EBITDA | -54.75 | |||||
EV-to-Forward-EBITDA | -67.4 | |||||
EV-to-Revenue | 19.91 | |||||
EV-to-Forward-Revenue | 17.38 | |||||
EV-to-FCF | -97.85 | |||||
Price-to-GF-Value | 2.61 | |||||
Earnings Yield (Greenblatt) % | -1.91 | |||||
FCF Yield % | -1.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GH
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Guardant Health Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,183.105 | ||
| EPS (TTM) ($) | -3.49 | ||
| Beta | 1.9777 | ||
| 3-Year Sharpe Ratio | 0.86 | ||
| 3-Year Sortino Ratio | 2.12 | ||
| Volatility % | 90.59 | ||
| 14-Day RSI | 62.55 | ||
| 14-Day ATR ($) | 7.671423 | ||
| 20-Day SMA ($) | 159.663 | ||
| 12-1 Month Momentum % | 148.52 | ||
| 52-Week Range ($) | 53.4 - 176.58 | ||
| Shares Outstanding (Mil) | 134.2 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guardant Health Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guardant Health Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-19 16:30 | In 182 days | ||
| Annual report for 2026 | 2027-02-19 | In 181 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-19 | In 181 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 16:30 | In 69 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 68 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-15 07:45 | In 25 days | ||
| Canaccord Genuity 46th Annual Growth Conference | 2026-08-12 15:00 | 165.09 (-1.12%) | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 16:30 | 144.07 (+0.31%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 144.07 (+0.31%) | ||
| General meeting for 2026 | 2026-06-17 09:30 | 127.34 (-2.19%) |
Guardant Health Inc Frequently Asked Questions
Guru Commentaries on NAS:GH
Guardant Health is a leader in liquid biopsy diagnostics, using a simple blood draw to detect and monitor cancer. The company holds a market-leading position in testing to help oncologists select targeted cancer therapies and continues to expand its portfolio across oncology and cancer screening. The company delivered another strong quarter, driven by continued strength in testing volumes and accelerating adoption of its Shield colorectal cancer screening test, prompting management to raise full-year revenue guidance. We believe Guardant is well positioned to benefit from increasing adoption of precision oncology and AI-enabled diagnostics, supported by a growing data repository, expanding reimbursement opportunities and several upcoming product catalysts.
Guardant Health is a leader in liquid biopsy diagnostics, using a simple blood draw to detect and monitor cancer. The company holds a market-leading position in testing to help oncologists select targeted cancer therapies and has continued to expand its portfolio across oncology and cancer screening. The company delivered better-than-expected results, driven by continued strength in oncology testing and accelerating adoption of its Shield colorectal cancer screening test, prompting another increase to full-year revenue guidance. We believe Guardant is well positioned to benefit from increasing adoption of precision oncology, expanding reimbursement and several upcoming product catalysts.
Press Release
Articles on Guardant Health Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
